EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer

Emilio Garcia-Mouronte iD, Emilio Berna-Rico iD, Belen de Nicolas-Ruanes, Carlos Azcarraga-Llobet iD, Luis Alonso-Martinez de Salinas, Sonia Bea-Ardebol

International Journal of Molecular Sciences · 29.06.2023 · 24 (13) · 10835

DOI: 10.3390/ijms241310835 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.06.2023. Verfasst von Emilio Garcia-Mouronte und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain. Hauptthemen laut MEDLINE: Skin Neoplasms, Precancerous Conditions, Antineoplastic Agents. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Instituto de Salud Carlos III MINECO and Peder Funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous cancers are, by far, the most common malignant neoplasms of the human being. Due to the great array of clinical conditions, their worldwide increasing incidence and the steady ageing of the population, non-invasive treatments modalities that show a good clinical response, a proper benefit–risk ratio and cosmetic results are becoming increasingly important in the clinical setting. Imiquimod is a topically applied immunomodulator which is often used in the management of several premalignant and malignant cutaneous disorders. This article is a review of the current literature on its mechanism of action, pharmacokinetics, and therapeutical effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsPrecancerous ConditionsAntineoplastic AgentsHumansImiquimodAdjuvants, ImmunologicSkinAdministration, CutaneousImmunotherapyAminoquinolines

Stichwörter der Autor:innen

actinic keratosisbasal cell carcinomaimiquimodimmunomodulationimmunotherapymelanomaskin neoplasmstopical administration

Substanzen

ImiquimodAdjuvants, ImmunologicAminoquinolinesAntineoplastic Agents

Autor:innen und Institutionen

  • Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain.

ORCID-Profile: Emilio Garcia-Mouronte, Emilio Berna-Rico, Carlos Azcarraga-Llobet

Förderung

  • Instituto de Salud Carlos III
  • Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal
  • Instituto de Salud Carlos III MINECO and Peder Funds

Zitieren

APA

Garcia-Mouronte, E., Berna-Rico, E., de Nicolas-Ruanes, B., Azcarraga-Llobet, C., Alonso-Martinez de Salinas, L., & Bea-Ardebol, S. (2023). Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer. International Journal of Molecular Sciences, 24(13), 10835. https://doi.org/10.3390/ijms241310835

Vancouver

Garcia-Mouronte E, Berna-Rico E, de Nicolas-Ruanes B, Azcarraga-Llobet C, Alonso-Martinez de Salinas L, Bea-Ardebol S. Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer. International Journal of Molecular Sciences. 2023;24(13):10835. doi:10.3390/ijms241310835

BibTeX
@article{GarciaMouronte2023,
  author = {Garcia-Mouronte, Emilio and Berna-Rico, Emilio and de Nicolas-Ruanes, Belen and Azcarraga-Llobet, Carlos and Alonso-Martinez de Salinas, Luis and Bea-Ardebol, Sonia},
  title = {Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {13},
  pages = {10835},
  doi = {10.3390/ijms241310835}
}
Kostenlos starten →